ICU Medical (ICUI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
13 May, 2026Opening remarks and agenda
Meeting conducted virtually to increase stockholder participation and was recorded for rebroadcast.
Introduction of directors, executive officers, auditors, and meeting officials.
Explanation of voting procedures and meeting rules, including Q&A format.
Board and executive committee updates
Board nominees introduced, including current directors and executive officers.
Auditors for the upcoming year introduced and available for questions.
Shareholder proposals
Proposal to establish a 10% shareholder special meeting right presented by John Chevedden.
Board recommended voting against the 10% threshold proposal, supporting a 25% threshold instead.
Chevedden criticized the 25% threshold as too restrictive and complex.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ICU Medical
- Adjusted EPS rose 15% to $1.97 as organic revenue grew 1% despite a 12% revenue decline.ICUI
Q1 202614 May 2026 - Margin expansion, pump upgrades, and consumables innovation drive a positive outlook.ICUI
2026 KeyBanc Capital Markets Healthcare Forum29 Apr 2026 - Infusion-focused growth, margin expansion, and share repurchases drive future value.ICUI
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Shareholders will vote on directors, governance reforms, and executive pay, with ESG in focus.ICUI
Proxy filing2 Apr 2026 - Key votes include director elections, auditor ratification, and expanded shareholder rights.ICUI
Proxy filing2 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and governance reforms, with board-backed ESG focus.ICUI
Proxy filing23 Mar 2026 - Innovation, unified platforms, and margin expansion drive growth and future capital returns.ICUI
47th Annual Raymond James Institutional Investor Conference9 Mar 2026 - 2026 guidance targets $400–$430M adjusted EBITDA and low- to mid-single-digit organic growth.ICUI
Q4 202519 Feb 2026 - Q2 revenue up 8.6%, net loss widens, but full-year earnings guidance is raised.ICUI
Q2 20242 Feb 2026